7.1 AFLIBERCEPT 4 mg 0.1 mL injection, 1 x 0.1 mL vial, 4 mg 0.1 mL injection, 1 x 0.09 mL syringe; Eylea®; Bayer Australia Ltd. - X Factor - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-03-16 01:05:14 Ranibizumab Bevacizumab Vascular endothelial growth factor Macular degeneration Macular edema Pharmaceutical Benefits Scheme Central retinal vein occlusion Off-label use Macula of retina Medicine Ophthalmology Health		7.1 AFLIBERCEPT 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea®; Bayer Australia Ltd. Add to Reading List Source URL: www.pbs.gov.au Download Document from Source Website File Size: 143,64 KB Share Document on Facebook

	MACULART meeting PARISFIRST ANNOUNCEMENTJUNE 2015 DocID: 1auUM - View Document
	Low vision medical certiﬁcate Low Vision Medical Certificate DocID: 17YqE - View Document
	PDF Document DocID: 17jFd - View Document
	Supplement to March 2015 Ranibizumab: Expanding DocID: 13pZp - View Document
	Public Summary Document – November 2014 PBAC Meeting 7.1 AFLIBERCEPT 4 mg/0.1 mL injection, 1 x 0.1 mL vial, DocID: 12sMx - View Document